Shenzhen Core Medical Technology CO.,LTD.
10
2
4
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
A Multicenter Registration Study of Complex High-risk PCI Patients
Role: collaborator
DuoCor 2 DOMINATE Study
Role: lead
DuoCor Ventricular Assist System Early Feasibility Study
Role: lead
Corheart 6 Left Ventricular Assist System Prospective, Multicenter, Single-arm Clinical Evaluation Trial
Role: lead
Interventional Ventricular Assist System for PCI in CHIP Patients
Role: lead
Corheart 6 LVAS Study
Role: lead
CorVad Myocardial Infarction Complicated with Cardiogenic Shock Trial
Role: lead
Efficacy and Safety of the CorVad Percutaneous Ventricular Assist System in Cardiogenic Shock
Role: lead
CorVad Percutaneous Ventricular Assist System Study
Role: lead
Corheart 6 LVAS LTFU
Role: lead
All 10 trials loaded